Last checked at 
(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stocks fell on Tuesday in a modest retreat from theprevious session's sharp rally, but major indexes remained ontrack for a positive first quarter and the S&P 500 was set forits ninth straight quarterly rise. The Dow Jones industrialaverage was down 0.44 percent at 17,896.5, the S&P 500 was down 0.34 percent at 2,079.09 and the NasdaqComposite was down 0.30 percent at 4,932.79.
** CHARTER COMMUNICATIONS INC, $197.595, +7.75 pct
The cable television operator said it would buy Bright HouseNetworks in a cash-and-stock deal valued at $10.4 billion toexpand in Florida. Charter said it would pay Advance Newhouse,the owner of Bright House, $2 billion in cash and the rest incommon and convertible preferred units of a newly createdpartnership for the deal.
** SYNTA PHARMACEUTICALS CORP, $1.91, -18.03 pct
The drug developer priced its offering of 22 million sharesat $1.75 each, a 25 percent discount to the stock's Monday'sclose.
** VAALCO ENERGY INC, $2.44, -22.04 pct
The oil and gas producer said it is abandoning its firstwell drilled offshore Angola as it was found to bewater-bearing.
** TECK RESOURCES LTD, $13.84, -9.36 pct
The Canadian miner and Antofagasta Plc denied that they were in talks about a merger after Bloombergreported that the two mining companies were in early stagetalks. Teck said in a statement that it was not in discussionswith Antofagasta "in relation to any form of transaction."
** RADA ELECTRONIC INDUSTRIES LTD, $3.06, +18.15pct
The Israel-based defense electronics contractor said itstactical 'active electronically scanned array' (AESA) radartechnology will be available in North America through deal withDRS Technologies Inc. DRS will produce and support tactical AESAradars as part of its tactical radar portfolio.
** INTERCEPT PHARMACEUTICALS INC, $284.85, -3.74pct
The drug developer priced its offering of 1.2 million sharesat $282 per share, a 5 percent discount to the stock's Mondayclose. The offering represents nearly 5 percent of company'soutstanding shares as of Feb. 15.
** CELLADON CORP, $20.74, -4.29 pct
The drug developer reported a wider fourth-quarter operatingloss due to higher costs.
** GREAT BASIN SCIENTIFIC INC, $3.59, +47.13 pct
The medical tests maker got a patent covering its method ofenhancing its molecular diagnostic test for a superbug. Thecompany said the patent will lower costs and speed up theprocess to detect the bacteria, Clostridium difficile.
** DELEK US HOLDINGS INC, $39.93, +0.05 pct
** ALON USA ENERGY INC, $16.94, +6.01 pct
Refiner Delek US Holdings said it is in talks to buy some orall of Alon Israel Oil Co Ltd, the parent company of Alon USAEnergy.
** MOVADO GROUP INC, $29.54, +15.26 pct
The luxury watch designer reported a better-than-expectedfourth-quarter profit, helped by lower taxes. The company alsosaid it would raise prices to offset the negative impact offoreign currency movements and that it would streamline "certainaspects" of its business.
** SORL AUTO PARTS INC, $3.6806, +10.53 pct
The Chinese auto parts maker reported a 14 percent jump infourth-quarter revenue, helped by new contracts and market sharegains.
** CORONADO BIOSCIENCES INC, $4.208, +18.87 pct
Analysts at MLV & Co raised their rating on the drugdeveloper's stock to "buy" from "hold", and raised their pricetarget by $5 to $7, saying Coronado's opioid treatment,tramadol, could win approval as early as 2016 following apositive late-stage study. MLV estimated the drug would earn $80million in annual sales by 2018.
** E-COMMERCE CHINA DANGDANG INC, $9.49, +13.25 pct
The Chinese online books and media retailer reported abetter-than-expected fourth-quarter earnings per Americandepositary share, helped by higher orders from mobile phones.
** EVER-GLORY INTERNATIONAL GROUP INC, $6.43, +11.63pct
The China-based apparel retailer reported a 52.4 percentrise in 2014 profit and a 25 percent rise in sales helped byrevenue gains in both its retail and wholesale businesses.
** INFINERA CORP, $19.5502, +0.72 pct
The network gear maker said Facebook Inc had deployedInfinera's technology in its European terrestrial network.
** GLAXOSMITHKLINE PLC, $46.05, -2.44 pct
** JOHNSON & JOHNSON, $101.2, -0.34 pct
GlaxoSmithKline has agreed to settle a lawsuit byJohnson & Johnson accusing it of using false advertising at thestart of the U.S. allergy season to grab market share.
** CBRE GROUP INC, $38.36, +5.36 pct
** JOHNSON CONTROLS INC, $50.65, +1.65 pct
Johnson Controls, the largest U.S. auto parts maker, said itwould sell its business that helps corporations manage theirreal estate energy needs to real estate services firm CBRE Groupfor $1.48 billion in cash. CBRE, the world's largest commercialreal estate services firm, said it expects the deal to add toadjusted earnings in 2016.
** ENDURANCE SPECIALTY HOLDINGS LTD, $61.37, -4.56pct
** MONTPELIER RE HOLDINGS LTD, $38.18, +0.08 pct
Property and casualty insurer Endurance will buy reinsurerMontpelier for about $1.83 billion in cash and stock, to expandinto the Lloyd's of London underwriting business. Montpeliershareholders will get 0.472 Endurance share and $9.89 in cashfor each share held, the companies said on Tuesday. Thisrepresents $40.24 per share for Montpelier, a 5.5 percentpremium to the stock's closing on Monday.
** GW PHARMA PLC, $91.97, +4.04 pct
The British maker of cannabis-based drugs said ithas started the second leg of a mid-stage trial testingEpidiolex to treat Dravet syndrome, a rare, treatment-resistantform of childhood epilepsyelectronics. Data from the trial isexpected at end of year and GW expects to submit a marketingapplication to the FDA in mid-2016. Epidiolex will also undergolate-stage testing to treat Lennox-Gastaut syndrome.
** J C PENNEY CO INC, $8.24, +5.24 pct
Analysts at Piper Jaffray raised their price target on thedepartment store chain's stock to $14, according to SeekingAlpha. The brokerage also raised its estimates for the companybased on inventory channel checks, Seeking Alpha reported.
** BIOCRYST PHARMACEUTICALS INC, $9.03, +5.37 pct
The drug developer said it won a U.S. government contractfor the continued development of its potential treatment forviral diseases, including Ebola. The 18-month contract includesa base value of $12.1 million to support manufacturing, as wellas $22.9 million in additional development options that can beexercised by the government.
** SPRINT CORP, $4.69, -1.26 pct
Sprint has agreed to settle a $131 million lawsuit accusingit of defrauding shareholders by issuing false and misleadingstatements about its tightened credit standards, improvements inits subscriber base, and the success of its merger with NextelCommunications Inc. (Compiled by Ramkumar Iyer in Bengaluru; Editing by SimonJennings)
